KYN Capital Group Inc (OTCMKTS:KYNC) Stock Cools Off After The Big Jump
There have been many stocks that have managed to clock significant gains over the course of the past month and one of those is the KYN Capital Group Inc (OTCMKTS:KYNC) stock. During the past month, the stock has emerged as one of the major gainers and managed to clock gains of as much as 138%.
In light of such enormous gains, it could be a good idea for investors to perhaps take a closer look at the company and some of the latest developments involving it. This morning the company is expected to be in considerable focus considering the fact that it finally released its Koinfold Pay app. The app is an ‘all in one payment solution’ mean for enterprises for receiving payments through digital assets.
It is an app that is going to allow businesses to accept payments in cryptocurrencies from any corner of the world. Merchants who use the app will be able to accept payments in some of the more popular cryptocurrencies like Litecoin, Bitcoin, Ethereum, and Bitcoin Cash among others. The payments are going to get straight to the merchant’s account and the whole thing is apparently quite quick as well as hassle-free.
In addition to that, fiat payments can also be made through the app, and more importantly, the Koinfold Pay app also works towards reducing price volatility as much as possible. Hence, it is no surprise that the stock is currently in focus among many investors and is expected to be so in the coming days.
Regen Biopharma (OTCMKTS:RGBP) Stock Resumes The Uptrend: Are You Excited?
The Regen Biopharma (OTCMKTS:RGBP) stock seems to have come into favor among many investors this week. Over the course of the past week, the Regen stock has been in the middle of a strong rally and has managed to clock gains of as much as 30%.
In light of such handsome gains, it is perhaps time for investors to take a closer look at the company and particularly at some of the recent developments. Yesterday the company released information with regards to the discussion about Regen Biopharma’s financial situation. The company revealed as of September 30, 2020, it had a cash balance of $0 but at the same time in 2019, its cash balance stood at $7885. The reduction in the cash balance was primarily down to the expenses incurred towards funding the operations of Regen.
In this regard, the company also revealed that it had an account receivable-related party to the tune of $71,186 as of September 30, 2019. On the other hand, the same figure on September 30, 2020, came in at $103192. On the other hand, it is also important to point out that the rise was also fuelled by the fact that the company got anniversary fees as well as royalties to the tune of $27424 from Zander at the end of each quarter.
Hence, it is clear to see that situation at the company may be improving and that might be one of the reasons behind the rally in the stock over the past week.